Background To compare drug regimens across clinical trials in Parkinson's disease (PD)
conversion formulae between antiparkinsonian drugs have been developed. These are …

Gradual degeneration and loss of dopaminergic neurons in the substantia nigra, pars
compacta and subsequent reduction of dopamine levels in striatum are associated with …

Parkinson disease (PD) treatment options have conventionally focused on dopamine
replacement and provision of symptomatic relief. Current treatments cause undesirable …

Importance Parkinson disease is the second most common neurodegenerative disease
worldwide. Although no available therapies alter the underlying neurodegenerative process …

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

The pathophysiology of Parkinson's disease (PD) tremor remains incompletely understood
and there is a lack of clinical trials specifically addressing its pharmacological treatment …

Objective To summarize the 2010 EFNS/MDS‐ES evidence‐based treatment
recommendations for the management of P arkinson's disease (PD). This summary includes …

Tremor is one of the primary motor symptoms of Parkinson's disease (PD), and it is
characterized by a highly phenomenological heterogeneity. Clinical and experimental …

Aromatic L-amino acid decarboxylase deficiency (AADCD) is a rare, autosomal recessive
neurometabolic disorder that leads to a severe combined deficiency of serotonin, dopamine …

Tremor is one of the core symptoms of Parkinson's disease (PD), but its mechanism is poorly
understood. The cerebellum is a growing focus in PD-related researches and is reported to …